Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UC San Diego to Assess Hypertension Drug Ramipril for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Altacereg

    Menu

    Altacereg

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ferrer Internacional

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction

              Details:

              The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.

              Lead Product(s): Aspirin,Ramipril,Simvastatin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Polypill

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: CNIC

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              University of California

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              UC San Diego to Assess Hypertension Drug Ramipril for Covid-19

              Details:

              Ramipril will be assessed for its potential to decrease the severity of Covid-19, lower intensive care unit admission rates, mechanical ventilators use, and all-cause mortality.

              Lead Product(s): Ramipril

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY